Characterisation of the path to idiopathic pulmonary fibrosis (IPF) and potential missed diagnostic opportunities

With a view to identifying potential opportunities for earlier referral to specialists and (ultimately) earlier diagnosis of IPF, this study aims to:
1. Evaluate patients’ patterns of HRU in the years preceding their IPF diagnosis.
2. Characterise the clinical features of patients at the time of their IPF diagnosis
Lead Investigator:
Luca Richeldi, National Institute for Health Research, Southampton Respiratory Biomedical Research Unit, University of Southampton, Southampton, UK
Research Team:
David Price: Professor of Primary Care Respiratory Medicine, University of Aberdeen, Aberdeen, UK; Owner of Optimum Patient Care Ltd and REG Chairman
Carlo Vancheri: “Regional Centre for Rare Lung Diseases”, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
Christopher Ryerson: Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Ian Glaspole: Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia
Ganesh Ragu: Division of Pulmonary & Critical Care Medicine, University of Washington, Washington, USA
Kevin Flaherty: Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
Vincent Cottin: National Reference Centre for Rare Pulmonary Diseases, Department of Respiratory Medicine, Claude Bernard Lyon University, Lyon, France
Toby Maher: National Institute for Health Research (NIHR) Clinician Scientist and Physician on the Interstitial Lung Disease Unit, Royal Brompton Hospital
Andrew Wilson: Norwich Medical School, University of East Anglia, Norwich, UK
Alan Kaplan: Family Physician Airways Group of Canada, Richmond Hill, Ontario, Canada
Martin Kolb: Department of Medicine, Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
Alison Chisholm: Chief Scientific Officer of REG, Cambridge, UK
Status: Active Study
Documents and Publications
Final Publications
Additional Material

Leave a Reply

Your email address will not be published. Required fields are marked *